Grace Therapeutics Director Edward Neugeborn Receives 12,200-Share Award

What Happened
Edward Neugeborn, a director of Grace Therapeutics, was granted 12,200 derivative shares (reported as an "A" — grant/award) on September 17, 2026. The filing reports an acquisition price of $0.00 per share (i.e., no cash paid at grant). Per the filing footnote, 50% of the award vested on the grant date and the remaining 50% vests in substantially equal monthly installments over 12 months, subject to continuous service.

Key Details

• Transaction date: 2026-09-17; filing date (Form 4): 2026-09-21 (timely filing).
• Reported price: $0.00 per share (derivative award, no cash consideration at grant).
• Number of shares/units granted: 12,200 (derivative securities).
• Vesting: 50% vested at grant; remaining 50% vests monthly over 12 months (see footnote F1).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: filed 4 days after the grant date; falls within the typical 2-business-day reporting window (timely).

Context
This was an equity award to a board member (compensation/retention grant), not a sale or cash purchase. Because it's a derivative award with a $0.00 per-share price, it functions like a stock award/RSU rather than a traditional option exercise requiring cash. Such grants are common for director compensation and do not by themselves indicate buying or selling sentiment.